Skip to main content
. 2025 Sep 25;2025:2040298. doi: 10.1155/arat/2040298

Table 2.

Adjusted mean change from baseline and 95% confidence interval, according to the treatment group.

N FTC/TAF/BIC 3TC/TDF/DOR p DTG/DOR p ∗∗
BMI, T1-T0 246 0.10 (−0.39–0.59) −0.07 (−0.45 to 0.31) 0.47 0.02 (−0.45–0.48) 0.78
BMI, T2-T0 193 0.03 (−0.67–0.73) 0.04 (−0.48–0.57) 0.96 0.02 (−0.65–0.70) 0.96
Weight (kg), T1-T0 300 0.4 (−1.1–1.9) 0.2 (−1.0–1.3) 0.75 0.1 (−1.4–1.5) 0.90
Weight (kg), T2-T0 227 0.4 (−1.5–2.4) 0.2 (−1.2–1.7) 0.79 −0.1 (−2.1 to 1.8) 0.79
Total cholesterol, T1-T0 337 −3 (−9 to 4) −23 (−29 to −17) < 0.0001 −6 (−16 to 4) 0.002
Total cholesterol, T2-T0 258 −8 (−17 to -0) −22 (−30 to -15) 0.004 −5 (−18 to 7) 0.014
LDL-cholesterol, T1-T0 311 −4 (−10 to 1) −16 (−22 to -11) 0.001 −1 (−10 to 8) 0.002
LDL-cholesterol, T2-T0 242 −7 (−13 to 0) −15 (−21 to -8) 0.055 −1 (−11 to 10) 0.016
HDL-cholesterol, T1-T0 318 −0 (−2 to 2) −2 (−4 to 0) 0.15 1 (−3–4) 0.12
HDL-cholesterol, T2-T0 252 −3 (−7 to −0) −2 (−5 to 1) 0.44 0 (−5–6) 0.47
Triglycerides, T1-T0 322 −7 (−20 to 6) −17 (−28 to -6) 0.20 −12 (−31 to 8) 0.62
Triglycerides, T2-T0 257 −6 (−21 to 9) −32 (−44 to -19) 0.009 −14 (−39 to 10) 0.23
TC/HDL-c, T1-T0 317 −0.04 (−0.12–0.20) −0.42 (−0.63 to −0.21) 0.002 −0.32 (−0.65 to −0.01) 0.59
TC/HDL-c, T2-T0 252 0.08 (−0.20–0.36) −0.55 (−0.81 to −0.29) 0.002 −0.33 (−0.76 to 0.11) 0.35
eGFR, T1-T0 343 −3.5 (−6.3 to −0.6) 0.6 (−2.2–3.4) 0.078 −7.8 (−12.2 to -3.5) 0.0005
eGFR, T2-T0 271 −3.4 (−7.3 to 0.4) 1.1 (−2.7–5.0) 0.05 −6.2 (−12.5 to 0.1) 0.03

Note: The multivariate models included baseline value of the variable, age, and previous regimen (TAF, TDF, or none; PI Y/N; NNRTI Y/N; INSTI Y/N). Regarding blood lipids, HCV coinfection, and statin use at baseline were also included. Age was excluded from the model for eGFR analysis because it was incorporated in the eGFR equation. HDL-c, high-density cholesterol; LDL-c, low-density cholesterol. Bold values represent p < 0.05 for change from baseline.

Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; TC, total cholesterol.

Comparison between 3-drug regimens.

∗∗Comparison between doravirine-including regimens.